相关实验视频

Updated: Jun 30, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

作为Bendamustine为Brexucabtagene的淋巴细胞减少,用于地幔细胞淋巴瘤的自身细胞治疗

Elise A Chong¹, Emeline R Chong¹, Dylan Therwhanger¹

¹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Transplantation and cellular therapy

|March 17, 2024

概括

班达穆斯丁是一种可行的,安全的替代性淋巴缺血疗法,在布雷克苏卡巴基因自细胞CAR T细胞治疗上治疗上衣细胞淋巴瘤之前,表现出与标准环胺/流达拉丁相比,可比的结果和减少的细胞衰竭.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

布雷克苏卡巴特基因自细胞 (brexu-cel) 是一种已批准的CD19导向的CAR T细胞疗法,用于复发性/阻断性地幔细胞淋巴瘤 (MCL).
由于fludarabine的短缺,需要在乳腺细胞输液之前探索替代性淋巴缺血 (LD) 方案.
环胺/流达拉丁 (cy/flu) 是标准的LD疗法,但其可用性可能有限.

研究的目的:

评估Bendamustine的可行性,安全性和有效性,作为MCL患者在Brexu-cel之前的替代LD疗法.
为了评估基于bendamustine的LD后的CAR T细胞扩张和持久性.
为了比较bendamustine LD的结果与历史的cy/flu LD数据.

主要方法:

在MCL患者接受Bendamustine或cy/flu LD后接受Brexu-cel的单个机构的回顾性研究.
使用2014年卢加诺指南评估的临床疗效.
在预先定义的时间点在外周血液样本中分析CAR T细胞扩张和持久性.

主要成果:

17名患者接受了班达穆斯丁LD; 5人接受了cy/fluLD.
班达穆斯丁队列:82%的客观反应率 (ORR),65%的完整反应率 (CRR).
与cy/flu相比,Bendamustine LD与细胞衰竭的频率较低和持续时间较短有关,观察到CAR T细胞扩张和持久性.

结论:

班达穆斯丁 (Bendamustine LD) 是一种可行的,安全的替代品,可以在MCL的Brexu-cel之前替代Cy/flu.
基于bendamustine的LD支持CAR T细胞的扩张和持久性.
bendamustine LD 的临床结果与标准的cy/flu LD 的临床结果相似.

关键词:

我们必须曲.布雷克苏卡巴泰基因自动化细胞在CAR T细胞中,在CART-T中,我们可以使用CAR-T.在 MCL 和 MCL 之间.地膜细胞淋巴瘤是什么

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...